Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-12-30

Clinical Trial Update: A Rollover Study to Provide Continued Treatment With Eltrombopag [Phase 4]

View source ↗

Summary

A phase 4 rollover study of eltrombopag to provide continued treatment for thrombocytopaenia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Eltrombopag (eltrombopag)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Thrombocytopaenia | Phase 4 | Status: COMPLETED | Results posted: 2022-12-30